Overview of the 2011 food and drug administration's circulatory system devices panel of the medical devices advisory committee meeting on the Zilver® PTX® Drug-Eluting peripheral stent

Cardiovascular Revascularization Medicine

Volumn 13, Issue 5, 2012, Pages 281-285

  Dvir, Danny ^a   Torguson, Rebecca ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Drug eluting stent; Food and Drug Administration; Peripheral arterial disease

Indexed keywords

CLOPIDOGREL; NITINOL; PACLITAXEL; TICLOPIDINE;

ADVISORY COMMITTEE; ANTICOAGULANT THERAPY; CLINICAL EFFECTIVENESS; DEVICE APPROVAL; DEVICE SAFETY; DRUG COATING; DRUG ELUTING STENT; FEMORAL ARTERY; FOOD AND DRUG ADMINISTRATION; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION;

ADVISORY COMMITTEES; ALLOYS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; DEVICE APPROVAL; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; EVIDENCE-BASED MEDICINE; FEMORAL ARTERY; HUMANS; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84866166328     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2012.05.003     Document Type: Review

References (12)

1. Diehm C., Schuster A., Allenberg J.R., Darius H., Haberl R., Lange S., Pittrow D., von Stritzky B., Tepohl G., Trampisch H.J. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004, 172:95-105.
2. Selvin E., Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 110:738-743.
3. Allison M.A., Criqui M.H., McClelland R.L., Scott J.M., McDermott M.M., Liu K., Folsom A.R., Bertoni A.G., Sharrett A.R., Homma S., Kori S. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006, 48:1190-1197.
4. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., Hiratzka L.F., Murphy W.R., Olin J.W., Puschett J.B., Rosenfield K.A., Sacks D., Stanley J.C., Taylor L.M., White C.J., White J., White R.A., Antman E.M., Smith S.C., Adams C.D., Anderson J.L., Faxon D.P., Fuster V., Gibbons R.J., Halperin J.L., Hiratzka L.F., Hunt S.A., Jacobs A.K., Nishimura R., Ornato J.P., Page R.L., Riegel B. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006, 47:1239-1312. American Association for Vascular Surgery, Society for Vascular SurgerySociety for Vascular Surgery, Society for Cardiovascular Angiography and InterventionsSociety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and BiologySociety for Vascular Medicine and Biology, Society of Interventional RadiologySociety of Interventional Radiology, ACC/AHA Task Force on Practice GuidelinesACC/AHA Task Force on Practice Guidelines, American Association of Cardiovascular and Pulmonary RehabilitationAmerican Association of Cardiovascular and Pulmonary Rehabilitation, National Heart, Lung, and Blood InstituteNational Heart, Lung, and Blood Institute, Society for Vascular NursingSociety for Vascular Nursing, TransAtlantic Inter-Society ConsensusTransAtlantic Inter-Society Consensus, Vascular Disease FoundationVascular Disease Foundation.
5. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., Bell K., Caporusso J., Durand-Zaleski I., Komori K., Lammer J., Liapis C., Novo S., Razavi M., Robbs J., Schaper N., Shigematsu H., Sapoval M., White C., White J., Clement D., Creager M., Jaff M., Mohler E., Rutherford R.B., Sheehan P., Sillesen H., Rosenfield K. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Suppl. 1):S1-S75. TASC II Working Group.
6. Schillinger M., Sabeti S., Loewe C., Dick P., Amighi J., Mlekusch W., Schlager O., Cejna M., Lammer J., Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006, 354:1879-1888.
7. Karnabatidis D., Spiliopoulos S., Diamantopoulos A., Katsanos K., Kagadis G.C., Kakkos S., Siablis D. Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia. J Endovasc Ther 2011, 18:1-12.
8. Duda S.H., Bosiers M., Lammer J., Scheinert D., Zeller T., Oliva V., Tielbeek A., Anderson J., Wiesinger B., Tepe G., Lansky A., Jaff M.R., Mudde C., Tielemans H., Beregi J.P. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006, 13:701-710.
9. Lammer J., Bosiers M., Zeller T., Schillinger M., Boone E., Zaugg M.J., Verta P., Peng L., Gao X., Schwartz L.B. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011, 54:394-401.
10. Meeting materials can be accessed at:, Accessed October 27, 2011. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/ucm240575.htm.
11. Dake M.D., Ansel G.M., Jaff M.R., Ohki T., Saxon R.R., Smouse H.B., Zeller T., Roubin G.S., Burket M.W., Khatib Y., Snyder S.A., Ragheb A.O., White J.K., Machan L.S., Zilver PTX Investigators Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011, 4:495-504.
12. Dake M.D., Scheinert D., Tepe G., Tessarek J., Fanelli F., Bosiers M., Ruhlmann C., Kavteladze Z., Lottes A.E., Ragheb A.O., Zeller T., Zilver P.T.X., Single-Arm Study Investigators Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-Arm clinical study. J Endovasc Ther 2011, 18:613-623.